PFKFB3 and colorectal carcinoma: Exosomal delivery of miR‐1915‐3p restored oxaliplatin sensitivity in resistant CRC cells by reducing epithelial‐to‐mesenchymal transition (EMT) markers and oncogene expression (PFKFB3, USP2), promoting apoptosis and reducing migration.